Indication
Advanced Malignant Tumors
16 clinical trials
21 products
Product
SHR-1901Clinical trial
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2025-12-28
Product
SG2918Product
LNF1901 Monoclonal AntibodyClinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of LNF1901 in Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Multicenter, Open Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-019 Monotherapy or Combination Anti-PD-1 Antibody in Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2025-03-22
Product
Anti-PD-1 antibodyProduct
LBL-019Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Activity of NBL-020 Injection in Subjects With Advanced Malignant Tumors.Status: Recruiting, Estimated PCD: 2025-08-01
Product
NBL-020Product
IAP0971Clinical trial
A Clinical Trial of Phase Ib/II to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2026-03-01
Product
anti-PD-1 antibodyClinical trial
A Phase Ib/II Study of AK112（PD-1 / VEGF Bispecific Antibody） in Combination With AK117（Anti-CD47 Antibody）With or Without Chemotherapy in Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-08-25
Product
AK117Product
AK112Product
ChemotherapyClinical trial
A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.Status: Recruiting, Estimated PCD: 2026-03-31
Product
LBL-033Clinical trial
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Product
SHR-2002Product
AK130Product
LNF1901Clinical trial
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK130 (TIGIT/TGF-β Bifunctional Fusion Protein) in Patients With Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2024-01-01
Product
IBC0966Clinical trial
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
SYH2043Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYH2043 in Patients With Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
IBB0979Clinical trial
A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBB0979 in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Product
Anti-PD-1 AntibodyClinical trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-05-30
Product
IBI319Clinical trial
An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-21
Product
AK127Clinical trial
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2025-11-01